Cargando…

Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes

The present study describes the development of DNA vaccines using the hemagglutinin-neuraminidase (HN) and fusion (F) genes from AF2240 Newcastle disease virus strain, namely pIRES/HN, pIRES/F and pIRES-F/HN. Transient expression analysis of the constructs in Vero cells revealed the successful expre...

Descripción completa

Detalles Bibliográficos
Autores principales: Firouzamandi, Masoumeh, Moeini, Hassan, Hosseini, Davood, Bejo, Mohd Hair, Omar, Abdul Rahman, Mehrbod, Parvaneh, Ideris, Aini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Veterinary Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808640/
https://www.ncbi.nlm.nih.gov/pubmed/27051336
http://dx.doi.org/10.4142/jvs.2016.17.1.21
_version_ 1782423498315005952
author Firouzamandi, Masoumeh
Moeini, Hassan
Hosseini, Davood
Bejo, Mohd Hair
Omar, Abdul Rahman
Mehrbod, Parvaneh
Ideris, Aini
author_facet Firouzamandi, Masoumeh
Moeini, Hassan
Hosseini, Davood
Bejo, Mohd Hair
Omar, Abdul Rahman
Mehrbod, Parvaneh
Ideris, Aini
author_sort Firouzamandi, Masoumeh
collection PubMed
description The present study describes the development of DNA vaccines using the hemagglutinin-neuraminidase (HN) and fusion (F) genes from AF2240 Newcastle disease virus strain, namely pIRES/HN, pIRES/F and pIRES-F/HN. Transient expression analysis of the constructs in Vero cells revealed the successful expression of gene inserts in vitro. Moreover, in vivo experiments showed that single vaccination with the constructed plasmid DNA (pDNA) followed by a boost with inactivated vaccine induced a significant difference in enzyme-linked immunosorbent assay antibody levels (p < 0.05) elicited by either pIRES/F, pIRES/F+ pIRES/HN or pIRES-F/HN at one week after the booster in specific pathogen free chickens when compared with the inactivated vaccine alone. Taken together, these results indicated that recombinant pDNA could be used to increase the efficacy of the inactivated vaccine immunization procedure.
format Online
Article
Text
id pubmed-4808640
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher The Korean Society of Veterinary Science
record_format MEDLINE/PubMed
spelling pubmed-48086402016-04-05 Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes Firouzamandi, Masoumeh Moeini, Hassan Hosseini, Davood Bejo, Mohd Hair Omar, Abdul Rahman Mehrbod, Parvaneh Ideris, Aini J Vet Sci Original Article The present study describes the development of DNA vaccines using the hemagglutinin-neuraminidase (HN) and fusion (F) genes from AF2240 Newcastle disease virus strain, namely pIRES/HN, pIRES/F and pIRES-F/HN. Transient expression analysis of the constructs in Vero cells revealed the successful expression of gene inserts in vitro. Moreover, in vivo experiments showed that single vaccination with the constructed plasmid DNA (pDNA) followed by a boost with inactivated vaccine induced a significant difference in enzyme-linked immunosorbent assay antibody levels (p < 0.05) elicited by either pIRES/F, pIRES/F+ pIRES/HN or pIRES-F/HN at one week after the booster in specific pathogen free chickens when compared with the inactivated vaccine alone. Taken together, these results indicated that recombinant pDNA could be used to increase the efficacy of the inactivated vaccine immunization procedure. The Korean Society of Veterinary Science 2016-03 2016-03-22 /pmc/articles/PMC4808640/ /pubmed/27051336 http://dx.doi.org/10.4142/jvs.2016.17.1.21 Text en © 2016 The Korean Society of Veterinary Science. http://creativecommons.org/licenses/by-nc/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Firouzamandi, Masoumeh
Moeini, Hassan
Hosseini, Davood
Bejo, Mohd Hair
Omar, Abdul Rahman
Mehrbod, Parvaneh
Ideris, Aini
Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes
title Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes
title_full Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes
title_fullStr Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes
title_full_unstemmed Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes
title_short Improved immunogenicity of Newcastle disease virus inactivated vaccine following DNA vaccination using Newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes
title_sort improved immunogenicity of newcastle disease virus inactivated vaccine following dna vaccination using newcastle disease virus hemagglutinin-neuraminidase and fusion protein genes
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808640/
https://www.ncbi.nlm.nih.gov/pubmed/27051336
http://dx.doi.org/10.4142/jvs.2016.17.1.21
work_keys_str_mv AT firouzamandimasoumeh improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes
AT moeinihassan improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes
AT hosseinidavood improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes
AT bejomohdhair improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes
AT omarabdulrahman improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes
AT mehrbodparvaneh improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes
AT iderisaini improvedimmunogenicityofnewcastlediseasevirusinactivatedvaccinefollowingdnavaccinationusingnewcastlediseasevirushemagglutininneuraminidaseandfusionproteingenes